Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
209 hedge funds and large institutions have $805M invested in Sorrento Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 85 increasing their positions, 40 reducing their positions, and 33 closing their positions.
147% more call options, than puts
Call options by funds: $162M | Put options by funds: $65.6M
113% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 40
109% more capital invested
Capital invested by funds: $386M → $805M (+$419M)
76% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 33
12% more funds holding
Funds holding: 186 → 209 (+23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.7M |
| 2 |
Morgan Stanley
New York
|
+$16.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.2M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$8.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$14.2M |
| 2 |
Coatue Management
New York
|
-$5.49M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.58M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.34M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.71M |
SRNE Hedge Fund Activity: Q3 2020 in Review
209 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2020, worth a combined $805M — up 109% from $386M a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new SRNE positions and 33 closed out — a net gain of 25 holders — while 85 added to existing stakes and 40 trimmed.
The largest buyer was BlackRock, adding an estimated $22.7M. The largest seller was Invesco, cutting an estimated $14.2M.
- 209 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2020, up from 186 in Q2 2020.
- Funds reported $805M of Sorrento Therapeutics, Inc. stock for Q3 2020, up 109% quarter-over-quarter.
- 58 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2020 and 33 closed out, a net change of +25 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2020 was BlackRock, an estimated $22.7M added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2020 was Invesco, an estimated $14.2M sold.
Based on aggregated 13F filings for Q3 2020.